ClinicalTrials.gg
RecruitingNCT05379738APALLOUpdated Jan 30, 2024

Impact of Adapted Physical Activity on Patient's Recovery Following Allogeneic Stem Cell Transplantation for Hematological Malignancy

An interventional study of 6 sessions of adapted physical activity after stem cell transplant in Haematological Malignancy, sponsored by Centre Hospitalier Universitaire de Nice. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-30.

Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 142 studies in Hematologic Neoplasms with a site in France — 49 open to participants now, 58 under way, 5 of them phase 3. Hematologic Neoplasms · France.

Planned enrollment
68th of 107
75 · median 106
Started
2022
with 9 others
No phase
29 of 142
12 open now
Primary completion
2026-12
later than 17 of 57 live
Registered
102nd of 142
by date
Lead sponsor
4 of 142
Centre Hospitalier Universitaire de Nice

Among the 142 studies in Hematologic Neoplasms with a site in France, this one is the 68th largest by planned enrollment of the 107 interventional ones that give a count, is one of 10 that started in 2022, is one of 29 with no phase, reaches primary completion later than 17 of the 57 other live ones, and was the 102nd registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

49 of the 142 studies in Hematologic Neoplasms with a site in France are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Hematologic Neoplasms with a site in France, or all of them as a file.
02

Study summary

It is a study about adaptated physical activity for patients receiving a stem cell transplantation. They will benefit of 6 adaptated individuals lessons at home between 1 month and 3 months after stem cell transplantation. The study's goal is to observe if adaptated activity has an positive impact on weight loss and on life quality.

03

Conditions studied

  • Haematological Malignancy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged 18 or more
  • Patient with social security
  • Patient who accept the study and sign the consent form
  • Patient programmed for an allogenic stem cell transplantation

Non inclusion criteria :

  • Patients with a guardianship
  • Patients with a significant additional physic or mental disease

Exclusion criteria

Exclusion criteria

  • Patients who did not receive an allogeniac stem cell transplantation
  • Patients still hospitalized between day 30 and day 100 after stem cell transplantation
  • Patients who finally refuses the study
  • Patients who develop a physical or mental incapacity to practice physical activity
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    adapted physical activity

    6 sessions of physical activity

    Other: 6 sessions of adapted physical activity after stem cell transplant

Interventions

  • Other6 sessions of adapted physical activity after stem cell transplant

    physical assessement before and after stem cell transplant: * weight loss * brachial muscle circumference * grip strength evaluation * short physical battery test psychometric assessment before and after stem cell transplant: * quality of life questionary * physical activities questionary

06

What researchers measure

Primary outcomes

  1. weight loss

    Body weight n in kilograms

    Time frame: before stem cell transplantation, 1 month , 3 months, 1 year after stem cell transplantation

  2. weight loss

    Calculation of the percent of body weight loss between the " before stem cell transplantation evaluation " and each evaluation after stem cell transplantation and after adaptated physical activity sessions.

    Time frame: before stem cell transplantation, 1 month , 3 months, 1 year after stem cell transplantation

Secondary outcomes

  1. patient's ability to attend the classes

    number of adaptated physical activity lessons attended by each patient after stem cell transplantation, calculation of feasibility

    Time frame: 3 months after stem cell transplantation

  2. body mass index

    Measure of weight and height to evaluate the nutriotional status of a patient

    Time frame: before stem cell transplantation, 1 month , 3 months, 1 year after stem cell transplantation

  3. brachial muscle circumference

    evaluation in centimeters of the brachial circumference to evaluate the evolution of the muscle circumference after stem cell transplantation and adaptated physical activity compared to the evaluation before stem cell transplantation. Using a measuring tape

    Time frame: before stem cell transplantation , 1 month , 3 months, 1 year after stem cell transplantation

  4. grip strength evaluation

    it is a measure of muscular strength

    Time frame: before stem cell transplantation , 1 month , 3 months, 1 year after stem cell transplantation

  5. short physical battery test

    it is a series of 3 physical tests to evaluate mobility the first test is a balance test (4 points), the second test is an evaluation of a walking speed (4 points) and the third test is a Chair rise test (4 points) The global test is on 12 points (12 is the better score)

    Time frame: before stem cell transplantation , 1 month , 3 months, 1 year after stem cell transplantation

  6. Quality of Life Questionary C30 (QLQ-C30)

    it is a score to evaluate the quality of life of patients facing illness The subscales scores are transformed to a 0 to 100 scale, with higher score on functionnal scales indicating better function and higher scores on sumptom scales indicating worse symptoms

    Time frame: before stem cell transplantation , 1 month , 3 months, 1 year after stem cell transplantation

  7. in house developped physical activities questionary

    it is a questionnary created especially for this study to evaluate on each step the capacity of each patient to maintain physical activities (social activities, autonomy at home for cooking and hygiene care, autonomy for transport to go to hospital appointments)

    Time frame: before stem cell transplantation , 1 month , 3 months, 1 year after stem cell transplantation

07

Study locations

1 of 1 sites recruiting
  • CHU NICE, hopital ARCHET 1, hématologie
    Nice, France
    Recruiting
    • SOLDATI Alizée · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Dec 2026, 54 months after the start.

Of 186 non-industry interventional studies with no phase under Hematologic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 125. This study's planned 54 months is above that.

Counting every sponsor, half of 192 studies reached it within 40 months; a quarter within 21 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2022
First posted
May 18, 2022
StartActual
Jun 10, 2022
Primary completionEst.
Dec 10, 2026
CompletionEst.
Apr 10, 2028
Last update
Jan 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05379738
Responsible party
Sponsor
First posted
May 18, 2022
Start date
Jun 10, 2022
Primary completion
Dec 10, 2026 (estimated)
Completion
Apr 10, 2028 (estimated)
Last update
Jan 30, 2024

Study contacts

SOLDATI Alizée
Contact
soldati.a@chu-nice.fr
04 92 03 96 27
LOSCHI Mickael, MD
Contact
04 92 03 90 25
SOLDATI Alizée
principal investigator · CHU NICE, hopital ARCHET 1, hématologie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion